[go: up one dir, main page]

PE20200732A1 - Formas de dosificacion oral y de liberacion controlada gastrorresistentes - Google Patents

Formas de dosificacion oral y de liberacion controlada gastrorresistentes

Info

Publication number
PE20200732A1
PE20200732A1 PE2019002573A PE2019002573A PE20200732A1 PE 20200732 A1 PE20200732 A1 PE 20200732A1 PE 2019002573 A PE2019002573 A PE 2019002573A PE 2019002573 A PE2019002573 A PE 2019002573A PE 20200732 A1 PE20200732 A1 PE 20200732A1
Authority
PE
Peru
Prior art keywords
controlled release
gastrore
subject
oral dosage
dosage forms
Prior art date
Application number
PE2019002573A
Other languages
English (en)
Inventor
Emmanuelle Georgi
Jay Saoud
Remy Luthringer
Sandra Werner
Nadine Noel
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62904624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20200732(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of PE20200732A1 publication Critical patent/PE20200732A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripcion se refiere a formas de dosificacion de liberacion controlada gastrorresistentes que comprenden el Compuesto (I): o una sal y/o un solvato farmaceuticamente aceptable de este, las propiedades farmacocineticas de estas formas de dosificacion, y su preparacion. Las nuevas formas de dosificacion descritas en la presente son utiles para reducir el riesgo de prolongacion QT en un sujeto y para tratar un trastorno en un sujeto que lo necesita, p. ej., un sujeto diagnosticado con esquizofrenia, por ejemplo, en el tratamiento de los sintomas negativos en un sujeto diagnosticado con esquizofrenia que tiene el genotipo CYP2D6 EM.
PE2019002573A 2017-06-21 2018-06-21 Formas de dosificacion oral y de liberacion controlada gastrorresistentes PE20200732A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762523204P 2017-06-21 2017-06-21
PCT/US2018/038853 WO2018237207A1 (en) 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms

Publications (1)

Publication Number Publication Date
PE20200732A1 true PE20200732A1 (es) 2020-07-23

Family

ID=62904624

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019002573A PE20200732A1 (es) 2017-06-21 2018-06-21 Formas de dosificacion oral y de liberacion controlada gastrorresistentes

Country Status (14)

Country Link
US (3) US11464744B2 (es)
EP (1) EP3641732A1 (es)
JP (2) JP2020525436A (es)
CN (1) CN111511353A (es)
AU (2) AU2018290287B2 (es)
BR (1) BR112019027398A2 (es)
CA (1) CA3067031A1 (es)
CL (1) CL2019003743A1 (es)
CO (1) CO2019014496A2 (es)
IL (3) IL271606B2 (es)
MX (1) MX2023002994A (es)
PE (1) PE20200732A1 (es)
UA (1) UA127349C2 (es)
WO (1) WO2018237207A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4063357A1 (en) 2014-12-02 2022-09-28 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
JP2020525436A (ja) 2017-06-21 2020-08-27 ミネルバ・ニューロサイエンシズ・インコーポレイテッド 胃耐性制御放出経口剤形
JP2022511266A (ja) 2018-08-21 2022-01-31 田辺三菱製薬株式会社 陰性症状および障害を処置するため、神経可塑性を増大するため、ならびに神経保護を促進するためのロルペリドンの使用
IT201800011125A1 (it) * 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico
WO2023154927A1 (en) 2022-02-14 2023-08-17 Minerva Neurosciences, Inc. Use of roluperidone in preventing relapse in schizophrenia patients
WO2025090588A1 (en) 2023-10-24 2025-05-01 Minerva Neurosciences, Inc. Roluperidone for the treatment of lysosomal storage disorders and their symptoms

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3888340T2 (de) 1988-01-21 1994-06-30 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
WO1991006297A1 (en) 1989-10-27 1991-05-16 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
CA2134077C (en) 1992-04-23 2002-05-21 Thaddeus R. Nieduzak 4-imidomethyl-1-[2'phenyl-2'oxoethyl-]piperidines as serotonin 5ht2-antagonists, their preparation and use in therapy
KR100815772B1 (ko) 2000-02-29 2008-03-20 미쯔비시 웰 파마 가부시키가이샤 신규 고리상 아미드 유도체
BR0114272A (pt) 2000-09-29 2003-08-26 Solvay Pharm Bv Formulação farmacêutica de liberação prolongada independente da força iÈnica
CN102335116A (zh) 2003-10-29 2012-02-01 惠氏有限责任公司 包含aplindore和其衍生物的缓释药物组合物
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
TW200616608A (en) 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
PE20061490A1 (es) 2005-06-06 2007-02-09 Merck Sharp & Dohme Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
WO2007092535A2 (en) 2006-02-07 2007-08-16 Mitsubishi Tanabe Pharma Corporation 4-acylaminopyridine derivative mediated neurogenesis
CA2569776A1 (en) 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
CN101273982A (zh) 2007-03-30 2008-10-01 田边三菱制药株式会社 预防和/或治疗抑郁症的药物
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
EP2246331A1 (en) 2009-04-24 2010-11-03 Westfälische Wilhelms-Universität Münster NR2B-selective NMDA-receptor antagonists
PL2471518T3 (pl) 2009-05-18 2018-01-31 Sigmoid Pharma Ltd Kompozycja zawierająca kropelki oleju
TW201206502A (en) 2010-06-16 2012-02-16 Teijin Pharma Ltd Controlled release nucleated tablet
HUE058736T2 (hu) 2010-07-20 2022-09-28 Minerva Neurosciences Inc Gyûrûs amidszármazékok alkalmazási módszerei szigma receptor közvetített rendellenességek kezelésére
SMT202300413T1 (it) 2010-07-20 2024-01-10 Minerva Neurosciences Inc Metodi di utilizzo di derivati di ammide ciclica per trattare schizofrenia e relativi sintomi
US8937900B2 (en) 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
MX2013010598A (es) 2011-03-17 2014-01-08 Lupin Ltd Composiciones farmaceuticas de liberacion controlada de inhibidor de recaptacion de serotonina selectivo.
AU2012297569B2 (en) * 2011-08-16 2017-11-09 Baker Heart and Diabetes Institute Controlled-release formulation
AU2014239883B2 (en) * 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
CN104586771B (zh) * 2013-10-30 2018-01-16 广州朗圣药业有限公司 一种盐酸坦洛新缓释微丸制剂
BR112016025427A2 (pt) * 2014-04-30 2017-08-15 Incyte Corp processos de preparação de um inibidor de jak1 e formas do mesmo
WO2015174534A1 (ja) 2014-05-16 2015-11-19 武田薬品工業株式会社 含窒素複素環化合物
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
KR102425303B1 (ko) * 2014-08-13 2022-07-25 세다르스-신나이 메디칼 센터 항-메탄생성 조성물 및 그것의 용도
EP4063357A1 (en) * 2014-12-02 2022-09-28 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
US10617650B2 (en) * 2015-10-16 2020-04-14 Merck Sharp & Dohme Corp. Process for preparing formulations for gastrointestinal-targeted therapies
TWI820001B (zh) 2016-05-25 2023-11-01 日商田邊三菱製藥股份有限公司 醫藥組成物的用於製造非思覺失調症病患之負性症狀治療劑的用途
JP2020525436A (ja) 2017-06-21 2020-08-27 ミネルバ・ニューロサイエンシズ・インコーポレイテッド 胃耐性制御放出経口剤形
JP2022511266A (ja) 2018-08-21 2022-01-31 田辺三菱製薬株式会社 陰性症状および障害を処置するため、神経可塑性を増大するため、ならびに神経保護を促進するためのロルペリドンの使用
WO2020264486A1 (en) 2019-06-28 2020-12-30 Teva Czech Industries S.R.O Solid state forms of roluperidone and salts thereof
WO2023154927A1 (en) 2022-02-14 2023-08-17 Minerva Neurosciences, Inc. Use of roluperidone in preventing relapse in schizophrenia patients

Also Published As

Publication number Publication date
AU2018290287A1 (en) 2020-01-16
AU2024219717A1 (en) 2024-10-03
JP2023175778A (ja) 2023-12-12
US12048768B2 (en) 2024-07-30
AU2018290287B2 (en) 2024-06-13
EP3641732A1 (en) 2020-04-29
CO2019014496A2 (es) 2020-04-01
CA3067031A1 (en) 2018-12-27
JP2020525436A (ja) 2020-08-27
RU2020102015A (ru) 2021-07-21
US20220401368A1 (en) 2022-12-22
US11464744B2 (en) 2022-10-11
RU2020102015A3 (es) 2021-10-04
IL271606B1 (en) 2024-01-01
IL319156A (en) 2025-04-01
IL271606B2 (en) 2024-05-01
CL2019003743A1 (es) 2020-07-03
US20250009665A1 (en) 2025-01-09
IL308650A (en) 2024-01-01
UA127349C2 (uk) 2023-07-26
WO2018237207A1 (en) 2018-12-27
BR112019027398A2 (pt) 2020-07-07
US20190038561A1 (en) 2019-02-07
MX2023002994A (es) 2023-09-15
IL271606A (en) 2020-02-27
CN111511353A (zh) 2020-08-07
IL308650B1 (en) 2025-04-01

Similar Documents

Publication Publication Date Title
CO2019014496A2 (es) Formas de dosificación oral y de liberación controlada gastrorresistentes
CO2020003478A2 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
MX2015011473A (es) Compuesto de fosforamidato de nucleosido novedoso y su uso.
CY1121735T1 (el) 7-benzyλ-10-(2-meθyλobenzyλ)-2,6,7,8,9,10-eξaϋδpoϊmiδazo[1,2-α]πυριδο[4,3-d]πυριμιδιν-5(3η)-ονη για χρηση στην αγωγη του καρκινου
ECSP18087352A (es) Formulaciones de un inhibidor de lsd1
MX385678B (es) Gamma-carbolinas heterocíclicas fusionadas sustituidas, composiciones farmacéuticas y métodos de uso.
MX2019007474A (es) Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
MX2018012379A (es) Degradadores de proteinas de bromodominio y dominioextraterminal (bet).
MX2020007485A (es) Compuestos antiproliferativos y metodos de uso de los mismos.
MX2015015228A (es) Sobetirome en el tratamiento de enfermedades de mielinizacion.
AR100006A1 (es) Derivados de tubulisina
CL2020001797A1 (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas.
GT201500086A (es) Análogos de 2'-cloro nucleósido para infección por vhc
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
AR101740A1 (es) Terapia de combinación y composiciones
UY36285A (es) Compuestos que inhiben la proteína mcl-1
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
MX2019009114A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
NI201800071A (es) Compuestos de isoindol
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.